Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „differences“
Suchtreffer
Begriffe & Kennungen
Abnormal limb bone morphology
Eintrag öffnenAccofil · 4.8 · Geriatric Use No overall differences in safety or effectiveness were observed between subjects over 65 years o
Eintrag öffnenAccofil · 4.8 · Geriatric Use No overall differences in safety or effectiveness were observed between subjects over 65 years o
Eintrag öffnenAccofil · 4.8 · Geriatric use No overall differences in safety or effectiveness were observed between subjects over 65 years o
Eintrag öffnenAccofil · 4.8 · Geriatric use No overall differences in safety or effectiveness were observed between subjects over 65 years o
Eintrag öffnenAfstyla · 4.8 · Paediatric population No age-specific differences in adverse reactions were observed between paediatric and ad
Eintrag öffnenAltuvoct · 4.8 · No age-specific differences in adverse reactions were observed between paediatric and adult patients.
Eintrag öffnenBekemv · 4.8 · No overall differences in safety were reported between elderly (≥ 65 years) and younger refractory gMG patient
Eintrag öffnenBenepali · 4.8 · There were no differences in rates of infection among patients treated with etanercept and those treated with
Eintrag öffnenBenepali · 4.8 · There were no differences in rates of infection among patients treated with etanercept and those treated with
Eintrag öffnenBlitzima · 4.8 · In GPA/MPA Study 2, no clinically meaningful differences between the two treatment arms or decreases in total
Eintrag öffnenBortezomib Accord · 4.8 · Notable differences in the safety profile of bortezomib administered subcutaneously versus intravenously as si
Eintrag öffnenBortezomib Accord · 4.8 · Notable differences in the safety profile of bortezomib administered subcutaneously versus intravenously as si
Eintrag öffnenBortezomib Fresenius Kabi · 4.8 · Notable differences in the safety profile of bortezomib administered subcutaneously versus intravenously as si
Eintrag öffnenBortezomib Sun · 4.8 · Notable differences in the safety profile of bortezomib administered subcutaneously versus intravenously as si
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBylvay · 4.5 · No interaction studies have been performed in paediatric patients. No differences are expected between the adu
Eintrag öffnenCalquence · 4.5 · No clinically significant differences in acalabrutinib pharmacokinetics were observed when a 100 mg acalabruti
Eintrag öffnenCapecitabine Accord · 4.5 · Oxaliplatin No clinically significant differences in exposure to capecitabine or its metabolites, free platinu
Eintrag öffnen